TY  - JOUR
AU  - Shah, Neil P
AU  - Garcia-Gutierrez, Valentin
AU  - Jimenez-Velasco, Antonio
AU  - Larson, Sarah
AU  - Saussele, Susanne
AU  - Rea, Delphine
AU  - Mahon, François-Xavier
AU  - Levy, Moshe Yair
AU  - Gomez-Casares, Maria Teresa
AU  - Pane, Fabrizio
AU  - Nicolini, Franck-Emmanuel
AU  - Mauro, Michael J
AU  - Sy, Oumar
AU  - Martin-Regueira, Patricia
AU  - Lipton, Jeffrey H
PY  - 2019
DO  - 10.1080/10428194.2019.1675879
UR  - http://hdl.handle.net/10668/15255
T2  - Leukemia & lymphoma
AB  - Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine kinase inhibitors to induce higher rates of sustained deep...
LA  - en
PB  - Taylor & Francis
KW  - CML-CP
KW  - Dasatinib
KW  - Deep molecular response
KW  - Imatinib
KW  - Major molecular response
KW  - Treatment-free remission
KW  - Aged
KW  - Dasatinib
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Leukemia, Myeloid, Chronic-Phase
KW  - Protein Kinase Inhibitors
KW  - Treatment Outcome
TI  - Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
TY  - research article
VL  - 61
ER  -